Candel Therapeutics clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 5 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Biodistribution of aglatimagene besadenovec Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden. After: Measure: Biodistribution of aglatimagene besadenovec.

Planned enrollment increased by 15 participants

Before: 30 participants (planned). After: 45 participants (planned).

Primary completion date changed

Before: Jun 2026. After: Aug 2026.

Check registry source